IFN exerts potent inhibitory activities against malignant melanoma cells in vitro and in vivo, but the mechanisms by which it generates its antitumor effects remain unknown.
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We examined the effects of interferon  (IFN) on the expression of human members of the Schlafen (SLFN) family of genes, a group of cell cycle regulators that mediate growth inhibitory responses. Using quantitative RT-real-time PCR we found detectable basal expression of all different human SLFN genes examined (SLFN5, SLFN11, SLFN12, SLFN13 and SLFN14), in malignant melanoma cells and primary normal human melanocytes, but SLFN5 basal expression was suppressed in all analyzed melanoma cell lines. Treatment of melanoma cells with IFNα resulted in induction of expression of SLFN5 in malignant cells, suggesting a potential involvement of this gene in the antitumor effects of IFNα. Importantly, stable knockdown of SLFN5 in malignant melanoma cells resulted in increased anchorageindependent growth, as evidenced by enhanced colony formation in soft-agar assays. Moreover, SLFN5 knockdown also resulted in increased invasion in 3D-collagen, suggesting a dual role for SLFN5 in the regulation of invasion and anchorage independent growth of melanoma cells.
Altogether, our
Introduction
The interferons (IFNs) are cytokines with important pleiotropic biological effects, including generation of antitumor responses and antiviral activities (1) (2) (3) . The ability of IFNs to induce antitumor responses in selective systems is highly relevant and, over the years, has had a major impact in the management of certain leukemias and solid tumors in humans. Malignant melanoma is one of the most IFNsensitive solid tumors. There has been extensive clinical evidence on the ability of IFNto generate antitumor effects in vitro in subset groups of patients with advanced metastatic malignant melanoma (4) (5) (6) (7) and IFNis now an FDA approved agent for the treatment of this malignancy.
An important outstanding issue in the IFN-research field has been the identification of specific mechanisms that account for differential sensitivity to the effects of IFNs. Despite the advances in the IFNsignaling field over the last 2 decades, the precise mechanisms and specific signals that account for the unique IFNsensitivity that some tumors exhibit remains largely unknown.
It is now well established that IFNs regulate transcription of target genes with important functional relevance via engagement of the JAK-STAT pathway (8) (9) (10) (11) . In recent years, additional levels of cellular regulation of IFN-inducible genes and their products have been identified, such as involvement of members of the PKC family (12) (13) (14) (15) (16) , the MAPK cascades (17) (18) (19) (20) (21) (22) , translational regulation via mTOR and 4EBP1 (23) (24) (25) (26) (27) (28) , modulation of histone acetylation (29) (30) (31) (32) (33) , and ISGylation (34) (35) (36) .
Although the identification of these pathways has established critical information on the mechanisms by which IFNs control transcription of distinct target genes and regulation of mRNA translation, the identity of specific genes that may account for the induction of the antiproliferative and antitumor effects of IFNs remains to be established. We have previously shown that IFNs induce mouse SLFN genes in murine hematopoietic progenitors and fibroblasts in a STAT1-and/or p38 MAPK-dependent manner and that the SLFN2 gene, which is mouse IFN-inducible, mediates growth inhibitory effects and anchorage independent growth of NIH3T3 and L929 fibroblasts (37) 
Cell
Proliferation Assays Cell proliferation assays using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method were performed as previously described (39, 40) .
Soft Agar Assays
Anchorage independent cell growth, was analyzed in soft agar assays, as previously described (37, 41) . For these studies, cells were plated in the absence or in the presence of 1-2x10 3 IU/ml IFN, as indicated, and colony formation was assessed after 7 days of culture.
3D Collagen invasion Assay
Invasion in 3D collagen was analyzed in a radial invasion assay, essentially as previously described (42) . Briefly, 100,000 cells were suspended in 2.2 % w/v collagen and allowed to form a cylinder shaped plug. The plug was then inserted in an additional layer of collagen, to allow formation of a core with a clean border between cells and the surrounding collagen. Wells were overlaid with media and the distance of invading cells leaving the core was determined at the indicated times, using the Carl-Zeiss AxioVision software tool.
Immunofluorescence detection of SLFN5 subcellular localization Cells were grown onto glass cover slips in the presence or absence of IFN. For SLFN5 detection, cells were treated for 48 hours with 2x10 3 IU/ml IFN fixed with formaldehyde, permeabilized and incubated with an antibody against SLFN5 followed by Alexa Fluor 488 secondary antibody. Additional staining was performed with DAPI (nuclei) and Phalloidin (actin). Cells were examined with a fluorescence microscope.
RNA Isolation and Real Time PCR Probes and Primers Cells were either treated with 5x10
3 IU/ml of IFN for the indicated times, as indicated. Isolation of RNA and conversion into cDNA was performed using the respective kits from Qiagen, according to the manufacturer's instructions.
Validated, inventoried probes and primers for real-time PCR and TaqMan PCR master mix were purchased from Applied Biosystems and used according to the manufacturer's instructions. The probes and primers were:
SLFN5, Hs00376501_m1; SLFN11, Hs 00430118_m1; SLFN12, Hs00430118_m1; SLFN13, Hs0043118 7_m1; and SLFN14, Hs03967006_cn. GAPDH (Hs99999905_m1) was used as an internal control. For the comparison of basal SLFN expression in various cells, a validated, universal human reference RNA from Agilent Technologies-Stratagene was used.
Generation
of Stable SLFN5 Knockdown Cells Generation of stable SLFN5 knockdown SKMEL28 cells was performed using standard approaches (37) . Briefly, two SLFN5 silencer select siRNA and control-scrambled sequences were used as templates in the Clontech shRNA sequence designer tool for Clontech pSIREN vectors. Plasmids were digested with restriction enzymes to verify the presence of siRNA encoding insert and then used for retroviral infection of SKMEL28 cells. Cells harboring pSIREN SLFN5-siRNA or pSIREN control-siRNA were green fluorescent and were selected by flow cytometry.
Results
We sought to determine the patterns of expression of different human SLFN mRNAs in normal human melanocytes and malignant melanoma cells, and the effects of IFN on such expression. In initial experiments, the expression of different SLFN genes in the IFN-responsive SKMEL2, SKMEL5, SKMEL28 and the IFN-resistant D10 melanoma cell lines, as well as normal human primary melanocytes was examined. Basal expression levels of SLFN5 (Fig. 1A) , SLFN11 (Fig.1B) , SLFN12 (Fig. 1C), SLFN13 (Fig. 1D) and SLFN14 (Fig. 1E) were first assessed. As shown in Fig. 1A , SLFN5 was expressed at a higher level of about 10-fold over reference in human primary melanocytes, compared to a 1-2-fold expression over reference in the various melanoma lines. The expression of all SLFN genes was generally at the lowest level in D10 cells (Fig. 1A-E) , while SLFN12 and SLFN13 were expressed at similar levels in both, primary melanocytes and in the melanoma cell lines SKMEL2 and SKMEL5 (Fig. 1C  and 1D ).
Altogether, these results established that SLFN5 expression is suppressed in the different melanoma cell lines, as compared to normal human melanocytes. Consistent with these findings, immunoblotting using an anti-SLFN5 antibody demonstrated clearly lower levels of expression of SLFN5 protein in the malignant melanoma cell lines as compared to primary human melanocytes (Fig. 1F) .
Previous work has established that the melanoma cell lines SKMEL2, SKMEL5 and SKMEL28 show variable responsiveness to IFN (43) (44) (45) , while D10 melanoma cells are IFN-resistant (46) . We obtained similar findings in experiments in which the effects of IFN on cell proliferation were examined using MTT assays ( Fig. 2A) , as well as in soft-agar assays examining the effects of IFN on anchorageindependent growth of malignant melanoma cells (Fig. 2B) . To determine whether IFN-inducible SLFN gene expression correlates with sensitivity to the inhibitory effects of IFN, SKMEL2, SKMEL5, SKMEL28, D10 and primary melanocytes were treated with IFN and induction of SLFN5, SLFN11, SLFN12 and SLFN13 mRNA expression was determined using quantitative real time RT-PCR. IFN -treatment only resulted in induction of SLFN5 in SKMEL2 (Fig. 3A) , SKMEL5 ( Fig. 3B ) and SKMEL28 (Fig. 3C ) cells, while none of the other SLFN genes was significantly inducible during the time points tested.
No IFN-dependent induction of SLFN5 was observed in the resistant D10 cells (Fig. 3D) , while all analyzed SLFN genes were inducible by IFN treatment of normal melanocytes (Fig. 3E) . SLFN5 induction was most prominent, at about 6-fold over baseline after 6 hours of treatment, followed by SLFN11 at about 5-fold over baseline, SLFN12 at 4-fold over baseline and SLFN13 with a modest but consistent 2.5-fold induction (Fig. 3E) .
To determine whether IFN-inducible SLFN5 expression required upstream engagement of Type I IFN-associated JAK kinases, we utilized Tyk2-deficient U1A cells, JAK1-deficient U4A cells and parental 2FTGH fibrosarcoma cells that express both Type I IFNRassociated Jak kinases (47) . Cells were treated IFN or were left untreated and SLFN5 expression was analyzed by quantitative real time RT-PCR. As shown in Fig. 3F, SLFN5 
In further studies, we used a specific antibody against SLFN5, to determine IFN-dependent induction SLFN5 protein expression in primary melanocytes and various IFN-sensitive and resistant malignant melanoma cell lines. The levels of SLFN5 protein increased after IFN-treatment in primary melanocytes (Fig. 4A ) and the IFN-responsive SKMEL2 (Fig. 4B) , SKMEL5 (Fig. 4C) , and SKMEL28 (Fig. 4D) lines, while there was no induction in IFN-resistant D10 cells (Fig. 4E) . Similarly, treatment with IFNalso resulted in upregulation of SLFN5 protein expression in the IFNresponsive SKMEL5 or SKMEL28 cell liness ( Fig. 4F and G) We then performed studies to determine the subcellular localization of IFN-inducible SLFN5. In a previous study in which the subcellular localization of murine HA-tagged SLFN proteins was analyzed, group I and II SLFNs were found to be localized in the cytosol, while all group III SLFNs were localized in the nucleus (48) . To determine whether a similar pattern of localization of human SLFN5 occurs, we performed studies using melanoma cells and primary melanocytes.
We examined the 5B, C and D) . In other studies, nuclear and cytosolic fractions were isolated from primary melanocytes or SKMEL 5 cells and equal amounts of protein were analyzed for the presence of SLFN5,. As shown in Fig. 5E , SLFN5 was clearly seen in the nucleus of primary melanocytes (Fig. 5E) . It was was also seen in nuclear fractions of SKMEL5 cells that were either not treated or treated with IFN for short times (Fig.  5F ).
To determine the functional relevance of baseline and IFN-inducible SLFN5 expression in human malignant melanoma cells, we generated SKMEL28 cells in which SLFN5 was stably knocked down using the pSIREN Zsgreen retroviral vector (Figs. 6A and  B) .
SKMEL28-ctrl-siRNA and SKMEL28-SLFN5-siRNA cells were plated in soft-agar in the presence or absence of IFN and colony formation was determined after crystal violet staining. Knockdown of SLFN5 clearly enhanced soft-agar colony formation of SKMEL28 cells (Fig. 6C and D ). There were also clearly higher numbers of colonies from IFN-treated SKMEL28-SLFN5-siRNA cells versus IFN-treated SKMEL28-ctrl-siRNA cells, suggesting that knockdown of SLFN5 expression has a negative impact on the ability of IFN to act as a suppressor on the growth potential of malignant melanoma cells Since invasion through collagen is essential for melanoma progression (49, 50), we sought to determine if SLFN5 knockdown would also enhance the ability of melanoma cells to invade through type I collagen. SKMEL28-ctrlsiRNA (control cells) and SKMEL28-SLFN5-siRNA cells were plated in a 3D-collagen invasion assay system and the ability of individual melanoma cells to invade was assessed. Individual SKMEL28 cells in which SLFN5 expression was knocked down invaded almost double as far into the surrounding collagen as compared to control cells (Figs. 7A and B) , indicating that malignant cell invasion is suppressed by SLFN5.
To determine whether increased invasion was due to SLFN5-regulation of matrix metalloproteinases (MMPs) we examined the effects of SLFN5 knockdown on MMPs that are expressed by SKMEL28 cells. SKMEL28 cells express MMP-2, MMP-14 and MMP-15, and as shown in Fig.  S1 (supplementary data), SLFN5 knockdown either had no significant effect or repressed MMP mRNA expression, suggesting a different mechanism for SLFN5-mediated suppression of cell invasion.
Discussion
The SLFN family proteins includes groups of genes that were originally identified for their growth regulatory properties (51) . The first Slfn gene to be identified, mouse Slfn1, was found to exhibit important regulatory effects on T-lymphocyte growth and development (51) . Subsequently, several additional mouse members of the family were identified that can be divided into three major groups based on sequence homology and domain structure (51, 52) . Group I (Slfns 1, 2) , group II (Slfns 3, 4) and group III (Slfns 5, 8, 9, 10 and 14) (51, 52). All SLFN proteins share a highly conserved N-terminal (AAA) domain involved in ATP/GTP binding (52, 53) , however only group III SLFNs harbor a motif found in superfamily I DNA/RNA helicases (52) . Group I and II SLFNs have been linked to growth suppression, differentiation and apoptosis (37, 48, 45, (51) (52) (53) (54) (55) (56) (57) (58) while group III SLFNs are associated with differentiation in various cells (52) . Interestingly, there is significant variability in the evolution and distribution of SLFN genes amongst species and not all SLFN genes can be found in primates or other mammals (59) . In fact, database analysis shows that humans only have group II and group III SLFNs, a fact that raises several questions. For instance, it has been recently shown that SLFN2 is a major contributor of T-cell quiescence and that an inactivating mutation in the Slfn2 gene results in immunodeficiency in mice harboring the elektra mutation (58, 60) .
Since humans have no homologue to SLFN2, at this time it is unknown which of the human SLFN genes, if any, may have similar effects on T-cell quiescence. Similar questions may apply for other functions of group I SLFN genes, especially as more information on the function and properties of these genes accumulates with time.
In the present study, we sought to define the functional relevance of human members of the SLFN family of proteins in the generation of the inhibitory effects of human IFN in malignant melanoma. Previous work from our laboratory (37) had established that several mouse SLFN members are induced in a Type I IFN-dependent manner and that mouse SLFN2 plays a key role in the regulation of normal mouse hematopoiesis. Importantly, our pervious studies had shown that gene transcription for all murine members of the SLFN family was IFN-inducible (37) , suggesting that other members of that family may be participating in the generation of other biological functions of IFNs. Because of the heterogeneity and differences between mouse and human systems, we analyzed gene expression for human members of the SLFN family, SLFN 5, 11, 12, and 13 . Surprisingly, only human SLFN5 was found to be inducible by human IFN in malignant melanoma cells, suggesting a specific role for this member in the generation of IFN-responses. Interestingly, when the basal expression of group II (SLFN12) or group III (SLFN 5, 11, 13, and 14) SLFN genes in primary melanocytes and melanoma cells was examined, SLFN5 was found to be highly abundant in normal melanocytes and consistently suppressed in all malignant different melanoma cell types studied.
Other SLFN genes were either not suppressed in all different malignant melanoma cell lines (SLFN12), or were not expressed at significant levels at baseline in normal melanocytes (SLFN 11, 13, 14) . This raises the possibility that suppression of SLFN5 expression in malignant melanoma cells may provide them with a growth advantage and promote tumorigenesis. To address the functional role of SLFN5 in melanoma cell growth and invasion, we generated SKMEL28 cells with stable SLFN5 knockdown and examined their ability to grow in soft-agar and invade through collagen. Our data establish that decreased expression of SLFN5 correlates with enhanced anchorage independent growth, as well as significantly increased invasion through collagen. As the protein is Type I IFN-dependent and the suppressive effects of IFN can not be optimally achieved in malignant melanoma cells with stable suppression of SLFN5 expression, these findings suggest an important role for SLFN5 in the suppressive effects of Type I IFNs on malignant melanoma cell growth and invasion.
To the best of our knowledge this is the first study directly implicating a member of the human Schlafen protein family in the control of cell invasion. These findings provide valuable new information that advances our understanding of the mechanisms of action of IFN in malignancies. Generally, the molecular mechanisms by which IFN is effective against malignant melanoma are not known. In particular, very little is known on the effects of IFNs on cellular events that promote growth and survival of malignant melanoma cells. The precise mechanism by which SLFN5 suppresses growth and invasion of malignant melanoma cells remains it be established. It is possible that SLFN5 regulates expression of other tumor suppressor genes, cell cycle regulators, or genes maintaining senescence and this remains to be determined in future studies. We have also shown that human SLFN5 is localized in the nucleus of human melanocytes and melanoma cells, consistent with what has been shown before for group III SLFNs (48) . Interestingly, like some other SLFNs, SLFN5 harbors a COG2865 region containing a helix-turn-helix motif (52) , suggesting DNA-binding activity. It will be interesting to examine in future studies if SLFN5 participates in transcriptional regulation of IFNsensitive genes and, if so, to identify its targets that may mediate its effects on anchorage independent growth and invasion in collagen. (E) over GAPDH was analyzed via RT-real-time PCR using specific primers and GAPDH as an internal control. In order to be able to compare the relative expression of SLFN genes in different cells, a universal human Stratagene reference RNA was used, which was also normalized to GAPDH in the samples. Means +S.E. of 3 independent experiments are shown. F. Lysates from HPMC or the indicated cell lines were separated by SDS-PAGE and immunoblotted with antibodies against SLFN5 or GAPDH, as indicated. D) . E-F. Nuclear and cytosolic fractions were isolated from lysates of primary melanocytes (E) or from lysates of SKMEL5 cells that had been treated with IFN for the indicated times (F). Equal amounts of protein were separated by SDS-PAGE and fractions were analyzed for subcellular localization of SLFN5 via immunoblotting. GAPDH and nuclear lamin A were analyzed in parallel to confirm proper separation of fractions. 
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